Crossmark

Understanding and managing the cardiovascular risks of androgen deprivation therapy for prostate cancer

Crossref DOI link: https://doi.org/10.1038/s41585-022-00671-5

Published Online: 2022-10-24

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Atalar, Kerem https://orcid.org/0000-0003-2338-8629
Rajan, Prabhakar https://orcid.org/0000-0001-8064-9878
License Information

Text and Data Mining valid from 2022-10-24

Version of Record valid from 2022-10-24
More Information

Article History

First Online: 24 October 2022

Competing interests

: P.R. declares research grant support from Ferring Pharmaceuticals. K.A. declares no competing interests.